http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110156823-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_366759959a879950036c4e69dc8fd483 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-025 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac70ece64c3a415ea7fbd3a7876a1e13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5348870b4c5e41d1f0c948dbc1120f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab014e9803555cad247c0f9ee364fca1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf7190dc9f2da1fa6599fe3ca0293986 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53f0b8bd3346a137145d3ef0b5536eb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b645ff45c8df2002f85a27f16f4b99f6 |
| publicationDate | 2019-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110156823-A |
| titleOfInvention | A kind of nontoxic methotrexate prodrug and preparation method thereof |
| abstract | The invention discloses a nontoxic methotrexate prodrug and a preparation method thereof, comprising the following two steps: (a) using 4-(hydroxymethyl) phenylboronic acid pinacol ester and p-nitrophenoxyformyl chloride As a raw material, it is dissolved in an organic solvent, and the reaction is fully stirred at 0 °C to synthesize an active small molecule that can be reversibly combined with methotrexate; (b) the active small molecule synthesized in the previous step, methotrexate and Triethylamine is dissolved in an organic solvent and fully reacted at room temperature and in the dark to prepare a methotrexate prodrug. The methotrexate prodrug prepared by the present invention itself has no toxicity, but can be decomposed to generate methotrexate under the action of reactive oxygen species (ROS), and exert its effect on the lesion site. The methotrexate prodrug prepared by the invention can be used for the treatment of diseases with a microenvironment rich in ROS such as tumors, which can not only have a therapeutic effect, but also avoid the toxic and side effects caused by the use of methotrexate, and has a very ideal disease treatment effect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113121580-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113121580-B |
| priorityDate | 2019-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.